GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Nanosphere Inc (NAS:NSPH) » Definitions » Peter Lynch Fair Value

Nanosphere (Nanosphere) Peter Lynch Fair Value : $-134.75 (As of Jun. 19, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Nanosphere Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Nanosphere's PEG is 1. Nanosphere's 5-Year TTM EBITDA Growth Rate is 25. Nanosphere's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 was $-5.39. Therefore, the Peter Lynch Fair Value for today is $-134.75.

As of today (2024-06-19), Nanosphere's share price is $1.69. Nanosphere's Peter Lynch fair value is $-134.75. Therefore, Nanosphere's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for Nanosphere's Peter Lynch Fair Value or its related term are showing as below:



NSPH's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.535
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Nanosphere Peter Lynch Fair Value Historical Data

The historical data trend for Nanosphere's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanosphere Peter Lynch Fair Value Chart

Nanosphere Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanosphere Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nanosphere's Peter Lynch Fair Value

For the Diagnostics & Research subindustry, Nanosphere's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanosphere's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Nanosphere's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Nanosphere's Price-to-Peter-Lynch-Fair-Value falls into.



Nanosphere Peter Lynch Fair Value Calculation

Nanosphere's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *-5.39
=-134.75

Nanosphere's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.39.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Nanosphere  (NAS:NSPH) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

Nanosphere's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=1.69/-134.75
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanosphere Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Nanosphere's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanosphere (Nanosphere) Business Description

Traded in Other Exchanges
N/A
Address
Nanosphere, Inc., was incorporated in 1999 in Delaware. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
Executives
Michael James Ward director 440 W. ONTARIO ST., CHICAGO IL 60654
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
R. Erik Holmlin director 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Gene S Cartwright director 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ann Wallin officer: Interim CFO 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062
Bruin Andre De director
Sheli Z Rosenberg director C/O EQUITY GROUP INVESTMENTS, L.L.C., TWO NORTH RIVERSIDE PLAZA, SUITE 600, CHICAGO IL 60606
Chad A. Mirkin director 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062
Brookside Capital Management Llc 10 percent owner C/O BAIN CAPITAL PUBLIC EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Brookside Capital Partners Fund Lp 10 percent owner C/O BAIN CAPITAL PUBLIC EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Brookside Capital Investors L P 10 percent owner C/O BAIN CAPITAL PUBLIC EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Venture Fund 2005, L.p. 10 percent owner C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Venture Partners 2005, L.p. 10 percent owner C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Venture Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116

Nanosphere (Nanosphere) Headlines

From GuruFocus

New Optical Disks May Boost the Gold Nanoparticles Industry

By Alberto Abaterusso Alberto Abaterusso 03-27-2018

NANOSPHERE, INC. Reports Operating Results (10-Q)

By gurufocus 10qk 05-06-2010

NANOSPHERE, INC. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010

NANOSPHERE, INC. Reports Operating Results (10-Q)

By gurufocus 10qk 11-05-2009